Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05108922 · ClinicalTrials.gov registry record · Phase 3
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 148
- Enrollment target
NCT05108922 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 148 participants.
The verdict
NCT05108922, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 148 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).
Interventions
- DRUG Donanemab
- DRUG Aducanumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2021-11-16 |
| Est. Completion | 2023-09-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05108922
The ClinicalTrials.gov registry entry for NCT05108922 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Donanemab is the first listed.
NCT05108922 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05108922 about?
NCT05108922 is a clinical study titled "A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)". The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).
What is the current status of trial NCT05108922?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 148 participants. The study started on 2021-11-16. Estimated completion is 2023-09-19.
What interventions are being tested in trial NCT05108922?
The interventions under investigation include: Donanemab (DRUG), Aducanumab (DRUG).
Who is sponsoring clinical trial NCT05108922?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.